Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Accera, Inc.
Accera, Inc. Completes $35 Million Series C Financing
November 28th, 2008
Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. Proceeds of this financing will be used to begin sales and marketing of the company's lead product, Axona(TM) (previously known as Ketasyn), which is scheduled to launch in the United States in the first quarter of 2009. Inventages was joined in this round by San Diego-based POSCO BioVentures and other previous private investors. Inventages and POSCO participated in the Company's Series A and B rounds. Steve...
Source: Health Business Week (2008-11-28)
|
